Panacea Biotec Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 18, 2025, 2:45 am

Competitors of Panacea Biotec Ltd

All Competitor Stocks of Panacea Biotec Ltd

Quarterly Result

Last Updated: August 20, 2025, 5:45 am

Below is a detailed analysis of the quarterly data for Panacea Biotec Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 166.70 Cr.. The value appears strong and on an upward trend. It has increased from 132.53 Cr. (Mar 2025) to 166.70 Cr., marking an increase of 34.17 Cr..
• For Expenses, as of Jun 2025, the value is 167.88 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 159.41 Cr. (Mar 2025) to 167.88 Cr., marking an increase of 8.47 Cr..
• For Operating Profit, as of Jun 2025, the value is -1.18 Cr.. The value appears strong and on an upward trend. It has increased from -26.88 Cr. (Mar 2025) to -1.18 Cr., marking an increase of 25.70 Cr..
• For OPM %, as of Jun 2025, the value is -0.71%. The value appears strong and on an upward trend. It has increased from -20.28% (Mar 2025) to -0.71%, marking an increase of 19.57%.
• For Other Income, as of Jun 2025, the value is 16.99 Cr.. The value appears to be declining and may need further review. It has decreased from 36.30 Cr. (Mar 2025) to 16.99 Cr., marking a decrease of 19.31 Cr..
• For Interest, as of Jun 2025, the value is 0.86 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.04 Cr. (Mar 2025) to 0.86 Cr., marking a decrease of 0.18 Cr..
• For Depreciation, as of Jun 2025, the value is 8.39 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 8.42 Cr. (Mar 2025) to 8.39 Cr., marking a decrease of 0.03 Cr..
• For Profit before tax, as of Jun 2025, the value is 6.56 Cr.. The value appears strong and on an upward trend. It has increased from -0.04 Cr. (Mar 2025) to 6.56 Cr., marking an increase of 6.60 Cr..
• For Tax %, as of Jun 2025, the value is 39.63%. The value appears to be improving (decreasing) as expected. It has decreased from 4,875.00% (Mar 2025) to 39.63%, marking a decrease of 4,835.37%.
• For Net Profit, as of Jun 2025, the value is 3.96 Cr.. The value appears strong and on an upward trend. It has increased from -1.99 Cr. (Mar 2025) to 3.96 Cr., marking an increase of 5.95 Cr..
• For EPS in Rs, as of Jun 2025, the value is 0.66. The value appears strong and on an upward trend. It has increased from -0.31 (Mar 2025) to 0.66, marking an increase of 0.97.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: November 15, 2025, 4:43 am

Growth

Last Updated: September 5, 2025, 12:05 pm

Balance Sheet

Last Updated: October 10, 2025, 2:41 pm

Below is a detailed analysis of the balance sheet data for Panacea Biotec Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 6.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 6.00 Cr..
• For Reserves, as of Mar 2025, the value is 829.00 Cr.. The value appears to be declining and may need further review. It has decreased from 836.00 Cr. (Mar 2024) to 829.00 Cr., marking a decrease of 7.00 Cr..
• For Borrowings, as of Mar 2025, the value is 22.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 21.00 Cr. (Mar 2024) to 22.00 Cr., marking an increase of 1.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 433.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 378.00 Cr. (Mar 2024) to 433.00 Cr., marking an increase of 55.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 1,290.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,241.00 Cr. (Mar 2024) to 1,290.00 Cr., marking an increase of 49.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 567.00 Cr.. The value appears to be declining and may need further review. It has decreased from 582.00 Cr. (Mar 2024) to 567.00 Cr., marking a decrease of 15.00 Cr..
• For CWIP, as of Mar 2025, the value is 128.00 Cr.. The value appears strong and on an upward trend. It has increased from 102.00 Cr. (Mar 2024) to 128.00 Cr., marking an increase of 26.00 Cr..
• For Investments, as of Mar 2025, the value is 3.00 Cr.. The value appears to be declining and may need further review. It has decreased from 40.00 Cr. (Mar 2024) to 3.00 Cr., marking a decrease of 37.00 Cr..
• For Other Assets, as of Mar 2025, the value is 592.00 Cr.. The value appears strong and on an upward trend. It has increased from 517.00 Cr. (Mar 2024) to 592.00 Cr., marking an increase of 75.00 Cr..
• For Total Assets, as of Mar 2025, the value is 1,290.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,241.00 Cr. (Mar 2024) to 1,290.00 Cr., marking an increase of 49.00 Cr..

Notably, the Reserves (829.00 Cr.) exceed the Borrowings (22.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Panacea Biotec Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
• For Basic EPS (Rs.), as of Mar 25, the value is -1.37. This value is below the healthy minimum of 5. It has decreased from -0.19 (Mar 24) to -1.37, marking a decrease of 1.18.
• For Diluted EPS (Rs.), as of Mar 25, the value is -1.37. This value is below the healthy minimum of 5. It has decreased from -0.19 (Mar 24) to -1.37, marking a decrease of 1.18.
• For Cash EPS (Rs.), as of Mar 25, the value is 4.26. This value is within the healthy range. It has decreased from 5.75 (Mar 24) to 4.26, marking a decrease of 1.49.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 136.18. It has increased from 133.94 (Mar 24) to 136.18, marking an increase of 2.24.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 136.18. It has increased from 133.94 (Mar 24) to 136.18, marking an increase of 2.24.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 91.21. It has decreased from 91.29 (Mar 24) to 91.21, marking a decrease of 0.08.
• For PBDIT / Share (Rs.), as of Mar 25, the value is -0.85. This value is below the healthy minimum of 2. It has decreased from 0.93 (Mar 24) to -0.85, marking a decrease of 1.78.
• For PBIT / Share (Rs.), as of Mar 25, the value is -6.54. This value is below the healthy minimum of 0. It has decreased from -5.06 (Mar 24) to -6.54, marking a decrease of 1.48.
• For PBT / Share (Rs.), as of Mar 25, the value is -1.30. This value is below the healthy minimum of 0. It has decreased from 0.24 (Mar 24) to -1.30, marking a decrease of 1.54.
• For Net Profit / Share (Rs.), as of Mar 25, the value is -1.42. This value is below the healthy minimum of 2. It has decreased from -0.24 (Mar 24) to -1.42, marking a decrease of 1.18.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -1.37. This value is below the healthy minimum of 2. It has decreased from -0.19 (Mar 24) to -1.37, marking a decrease of 1.18.
• For PBDIT Margin (%), as of Mar 25, the value is -0.93. This value is below the healthy minimum of 10. It has decreased from 1.02 (Mar 24) to -0.93, marking a decrease of 1.95.
• For PBIT Margin (%), as of Mar 25, the value is -7.16. This value is below the healthy minimum of 10. It has decreased from -5.53 (Mar 24) to -7.16, marking a decrease of 1.63.
• For PBT Margin (%), as of Mar 25, the value is -1.42. This value is below the healthy minimum of 10. It has decreased from 0.26 (Mar 24) to -1.42, marking a decrease of 1.68.
• For Net Profit Margin (%), as of Mar 25, the value is -1.55. This value is below the healthy minimum of 5. It has decreased from -0.26 (Mar 24) to -1.55, marking a decrease of 1.29.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is -1.49. This value is below the healthy minimum of 8. It has decreased from -0.20 (Mar 24) to -1.49, marking a decrease of 1.29.
• For Return on Networth / Equity (%), as of Mar 25, the value is -1.00. This value is below the healthy minimum of 15. It has decreased from -0.14 (Mar 24) to -1.00, marking a decrease of 0.86.
• For Return on Capital Employeed (%), as of Mar 25, the value is -4.34. This value is below the healthy minimum of 10. It has decreased from -3.32 (Mar 24) to -4.34, marking a decrease of 1.02.
• For Return On Assets (%), as of Mar 25, the value is -0.64. This value is below the healthy minimum of 5. It has decreased from -0.09 (Mar 24) to -0.64, marking a decrease of 0.55.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 0.2. It has increased from 0.01 (Mar 24) to 0.02, marking an increase of 0.01.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.02. This value is within the healthy range. It has increased from 0.01 (Mar 24) to 0.02, marking an increase of 0.01.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.44. There is no change compared to the previous period (Mar 24) which recorded 0.44.
• For Current Ratio (X), as of Mar 25, the value is 1.49. This value is below the healthy minimum of 1.5. It has decreased from 1.57 (Mar 24) to 1.49, marking a decrease of 0.08.
• For Quick Ratio (X), as of Mar 25, the value is 0.90. This value is below the healthy minimum of 1. It has decreased from 0.99 (Mar 24) to 0.90, marking a decrease of 0.09.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.09. This value is below the healthy minimum of 4. It has decreased from 1.11 (Mar 24) to 1.09, marking a decrease of 0.02.
• For Interest Coverage Ratio (X), as of Mar 25, the value is -1.35. This value is below the healthy minimum of 3. It has decreased from 1.60 (Mar 24) to -1.35, marking a decrease of 2.95.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -10.52. This value is below the healthy minimum of 3. It has decreased from -9.48 (Mar 24) to -10.52, marking a decrease of 1.04.
• For Enterprise Value (Cr.), as of Mar 25, the value is 2,612.25. It has increased from 620.65 (Mar 24) to 2,612.25, marking an increase of 1,991.60.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.67. This value exceeds the healthy maximum of 3. It has increased from 1.11 (Mar 24) to 4.67, marking an increase of 3.56.
• For EV / EBITDA (X), as of Mar 25, the value is -497.57. This value is below the healthy minimum of 5. It has decreased from 108.22 (Mar 24) to -497.57, marking a decrease of 605.79.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.83. This value exceeds the healthy maximum of 3. It has increased from 1.33 (Mar 24) to 4.83, marking an increase of 3.50.
• For Price / BV (X), as of Mar 25, the value is 3.24. This value exceeds the healthy maximum of 3. It has increased from 0.90 (Mar 24) to 3.24, marking an increase of 2.34.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.83. This value exceeds the healthy maximum of 3. It has increased from 1.33 (Mar 24) to 4.83, marking an increase of 3.50.
• For EarningsYield, as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.00.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness